Abacavir

證據等級: L5

預測適應症: 3 個

ABACAVIR: Antiretroviral Agent — Drug Repurposing Evaluation

One-Sentence Summary

Abacavir is a nucleoside analogue reverse transcriptase inhibitor (NRTI) used in the treatment of HIV infection. The TxGNN model has not generated any predicted new indications for this drug at the current data cutoff, and no clinical trials or literature supporting repurposing directions are available in this evidence pack.

Quick Overview

Item	Content
Original Indication	HIV infection (known from drug class; no Taiwan label available)
Predicted New Indication	— None predicted
TxGNN Prediction Score	— N/A
Evidence Level	L5 (No predictions or supporting studies)
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

There is currently no TxGNN prediction available for Abacavir. The model did not return any candidate new indications, so a mechanistic plausibility assessment cannot be performed at this time.

For reference, Abacavir is a carbocyclic synthetic nucleoside analogue. It is intracellularly converted to its active metabolite, carbovir triphosphate (CBV-TP), which competitively inhibits HIV-1 reverse transcriptase and terminates viral DNA chain elongation. However, detailed mechanism of action data was not included in this evidence pack (marked as a data gap).

Without a predicted indication, there is no basis to evaluate whether Abacavir's mechanism could be leveraged for a novel therapeutic use.

Clinical Trial Evidence

Currently no related clinical trials registered for any repurposing indication.

Literature Evidence

Currently no related literature available for any repurposing indication.

Taiwan Market Information

Abacavir currently holds no marketing authorizations in Taiwan (TFDA). No licensed products were identified during the query (2026-03-29).

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack. These represent blocking data gaps that must be resolved before any safety evaluation can proceed.

Data Gaps Identified

Gap ID	Category	Item	Severity	Impact	Remediation
DG001	Drug Level	TFDA Package Insert Warnings / Contraindications	Blocking	Cannot enter S1 safety preliminary assessment	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Impacts mechanistic relevance analysis	Query DrugBank API

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model has not generated any predicted new indications for Abacavir. Combined with the absence of Taiwan marketing authorization, missing safety data (blocking-level gap), and no supporting clinical or literature evidence, there is insufficient basis to advance this candidate through the repurposing pipeline.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline to confirm absence of candidate indications (or update to a newer model version)
Resolve DG001: Obtain TFDA package insert warnings and contraindications (blocking for safety assessment)
Resolve DG002: Retrieve detailed mechanism of action data from DrugBank API
If a future prediction is generated, gather clinical trial and literature evidence for the predicted indication
Assess Taiwan regulatory pathway feasibility given the drug's current unlicensed status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.